Upload
vuongdieu
View
249
Download
6
Embed Size (px)
Citation preview
A1
103 1 2
105
2 103/12/18
103 IEET 103 IEET//// 5 5 1 103/07/30 IEET 103/11/07 104 3
103-1 21 103/11/18 20
102-2 885 2,000
103-1 12/12 2,818 2,045 1 772 1,330
104 11/11 11/18
2,115 1,530 11/24-11/26
( 1 ) 420 104 11/11 11/18 38
A2
88 4 82 82
104 110 ( 103
) 229 1,792 103/12/15-12/23 02/09 02/10 ()
02/11-02/16 03/11 03/27 104 13 241
104/02/25-104/03/09 05/14 104 96 832
104/04/07-04/14 05/14 06/05 2 104
8 103
5 10 14 ( 5 9 )
103 12
615 23,112,047 ( 56 3,796,585 )
104 ( 6 ) 42 20,050,000
103 16 576,000
26.62% 25.66% 35.15 18.44% 1 38.035 5.42% 41.99 33.73%
A3
104 01/19 () 08/23-08/24 () 6
() 100 101 102 103 104 1 106 1 19 4 600 1 1 2 4 120
1. 103/10/03 20 5 5 34
2. 37 mentor 51 mentee 103/11/10 52
A4
3. 104/01/19-20 37 3
4. 104/01/15 102
1. 4 788 35 4.34
2. Future Faculty Program103/12/15 dos and don'ts
3. 10 198 25
TA 1. 103-1 TA 103/12/26
2. 102-2 TA 103/10/28 72 TA103/12/17 TA
3. TA Pilot 57 7 (32 TA)
1. YouTube EDU
2. 103-1 19 110 19
3. 75 1,921 739,189
4. 10 OCW 11
5. FACULTY+ 30 17 8 CEIBA 9 10 Ever Cam 11
6. MOOCs (Coursera)
A5
10 16 21112
1. 103 8
2. 103/11/24 3 5 104/05
3. 12
4. 11/28 12/15
104/01/31 104/02/28
1. 3 (1) 103/11/06
103/11/27 (2) 103-1 22
18 151 2. 103/11/17 102-2
103/12 104 1
3. 102 32 100% 2,787 103 10 24 31
103-2
(1)
104-1 (2)
A6
(3)
(4)
(5)
(6)(7)
(8)
()
(9) 2728 103/12/08
(10) ()
(11) ()
(12) ()
A7
(13) ()
(14)
3 1 () (15)
()
(16) () 104
17
18
() (19)
88 ()
A8
4
()
10302 EPM5044 849U0150 2/ / / 213
1
2
(1) (2)
:
(1)
(2)
Thiscourseisintendedforundergraduateandgraduatestudentswhohavethedesiretounderstandthebasicconceptsofmathematicalmodelinganditsapplicationstotheepidemiological
1
user 1
studyofinfectiousdiseases.Thecoursewillprovidestudentstodiscoverhowmathematicalconceptshelpusunderstandthespreadofinfectiouspathogensthroughdynamicpopulations.Studentswillexploreexistingmathematicalmodelsinpracticalcomputerlabsessions,andalsolearnhowtodeterminethekeyparametersinvolvedinthespreadofpathogens,theimpactofchangesintheseparameters,anddiscussthepublichealthpolicyimplications.Throughdiscussionsofpublishedpapers,studentswilllearnhowtocriticallyevaluateamodelingpaper,andhowtocommunicatethemodelingresultswithpolicymakers.
Thecoursehastwomajorobjectives:(1)introducebasicprinciplesofmathematicalmodelingmethodsand(2)emphasizethesignificanceofsimulationandmodelingtothestudyofinfectiousdiseaseepidemiology.
Weeklyreadings,writtenassignmentsandparticipationinclassdiscussionandcomputerlab.Thereisatakehomemidtermexamforevaluatingstudentstheabilityofimplementingadiseasetransmissionmodel.Studentsalsoneedtocompletetermprojectaddressingmathematicalorcomputermodelinginoneofinfectiousdiseasesoftheirchoice.
1.Keeling,M.J.andRohani,P.(2008)ModelingInfectiousDiseasesinHumansandAnimals.PrincetonUniversityPress.2.Vynnycky,E.andWhite,R.G.(2010)AnIntroductiontoInfectiousDiseaseModelling.OxfordUniversityPress.3.Anderson,R.M.andMay,R.M.(1992)InfectiousDiseasesofHumans:DynamicsandControl,OxfordUniversityPress4.Hannon,BandRuth,M(2009),DynamicModelingofDiseasesandPests,Springer
1 02/25IntroductiontoModelinginInfectiousDiseases
Epidemiology/
2 03/04 SIRModelandR0/
3 03/11 SimulatingSIREpidemics/
4 03/18 LatentPeriodandCarrierState/
2
5 03/25 SEIRModel/
6 04/01
7 04/08Modelingdiseasewithcomplexnaturalhistory:
tuberculosisasanexample
8 04/15ParameterEstimationandSensitivityAnalyses
9 04/22ModelingRealisticEpidemicInfectionrelatedMortality,
ImmunityWaning,andRiskStructure(1)/
10 04/29ModelingRealisticEpidemicInfectionrelatedMortality,
ImmunityWaning,andRiskStructure(2)/
11 05/06 *TakeHomeMidtermexam*
12 05/13 MidtermExamDiscussion/
13 05/20 AgeStructure/
14 05/27ControllingInfectiousDiseases:VaccinationandIsolation
/
15 06/03 StochasticDynamics/
16 06/10SpecialLectureSpatiotemporalmodelingofinfectious
diseases( )
17 06/17 Journalreadingandpresentation1/
18 06/24 Journalreadingandpresentation2/
1.
2.
journalreading3.
3
4.
NO. 1 Homework 40% 2 MidTermExam 30% 3 Termpresentation 30%
982 :4.96(982),4.47(992),4.73(1002),4.72(1012),4.68(1022)
4
1
4
()
1041
EPM5046 849U0170 01 3/ / 234 212
(MD,PhD) SCI SSCI
(PhDinStatistics) SCI 10 JohnWileyMarcelDekkerCRC/Chapman&Hall 2012 (FellowoftheAmericanStatisticalAssociation)
( 50 )
(1)
(2) 27 35 SAS
5
user 2
2
(3) (4)
(Projects)
(Oral
Presentations)
(Written
Reports)
(Oral Review and Discussion)
(5) 96 1
31
(1)
SAS
(2) SAS (Ceiba Website) Ceiba
(3) (In-depth Homework) (4) 3-5
(Projects)
(Oral Presentations)
(Written Reports)
(Oral Review and
Discussion)(Peer Review)
6
3
HotellingT2 SAS SPSS
Exampleofmultivariatedata,reviewofmatrixalgebra,testofmeans,multivariateanalysisofvariance,principalmultidimensionalscaling,principalcomponentanalysis,exploratoryandconfirmatoryfactoranalyses,clusteranalysis,discriminatanalysis,canonicalanalysis SAS SPSS
30%(takehome) 30% 40%
SAS SPSS (www.statedu.ntu.edu.tw) SAS SPSS
Manly,B.F.J.(2005)MultivariateStatisticalMethods:Aprimer,3rdEd. Chapman&Hall,NewYork. Morrison,D.F.(2005)MultivariateStatisticalMethods,4thEd,Duxbury Press,Belmont,CA Sharma,S.(1996)AppliedMultivariateTechniques,JohnWiley,NewYork Izenman,A.J.(2008)ModernMultivariateStatisticalTechniques,Springer, M.L.Shen(1998)AppliedMulitvariateAnalysis, ,
1 9/16/2015 IntroductionandExamplesofMultivariatedata:
2 9/23/2015 ReviewofMatrixAlgebra;SummarizationofMultivariateData:
3 9/30/2015 TestsofMeansI:HotellingT2OneSamplePairedSamples:
4 10/7/2015 TestsofMeansII:HotellingT2TwoIndependentSamplesProfileAnalysis:
7
4
5 10/14/2015 TestsofMeansIII:MultivariateAnalysisofVariance(MANOVA)LinearContrastsProfileAnalysis:
6 10/21/2015 MeasuringandTestingMultivariateDistance;ReductionofDimensionsI:MulidimensionalScaling:
7 10/28/2015 ReductionofDimensionsII:PrincipalComponentAnalysis(PCA):
8 11/4/2015 MidtermStudentsPresentation:Students
9 11/11/2015 CovarianceStructureI:ExploratoryFactorAnalysis(EFA):
10 11/18/2015 CovarianceStructureII:ExploratoryFactorAnalysis(EFA)ConfirmatoryFactorAnalysis(CFA):
11 11/25/2015 CovarianceStructureIII:ConfirmatoryFactorAnalysis(CFA)IntroductiontoStructuralEquations:
12 12/2/2015 ClassificationI:ClusterAnalysis: 13 12/9/2015 ClassificationII:DiscriminantAnalysis:
14 12/16/2015 CorrelationsbetweenTwoSetsofVariablesII:Canonical
Analysis: 15 12/23/2015 CorrelationsbetweenTwoSetsofVariablesI:Ordination
andCorrespondenceAnalysis: 16 12/30/2015 ApplicationsofMultivariateQuantitativeMethodsto
PublicHealthandPreventiveMedicine: ApplicationsofMultivariateQuantitativeMethodstoBiology,AgricultureandBiomedicalResearch:
17 12/6/2016 FinalStudentsPresentation:Students
18 12/13/2016 FinalStudentsPresentation:Students
(1) 96 1
SAS
8
5
(2) SAS (Ceiba Website) Ceiba
(3) (In-depth Homework) (4) 3-5 8
(Projects)
(Oral Presentations)
(Written
Reports)
(5) (Oral Review and Discussion)
(Peer Review)
(6)
(7) - :15 :3:2
(8) - :28 : 4 :4:4
(9) 10%:
(10)
NO. 1 30% 2 30% 3 40%
(1) (2) (3) (4) (
)(5) (6) - 991: 4.85; 1001:4.38; 1011: 4.66; 1021: 4.66;
31
9
6
4 4.64
101 102
(7)
,
, ;
(a)
(b) (1) (2) (3) (4) (5) (6) (7) CEO(8) Theassociationbetweenobesityandbiochemicalsubstances(9) Thecomparisonofthefirsttermbetweentwogovernments(10) (11) (12) NBA (13) (14) Discussionthefactorsassociatedwithdepressionusingmultivariateanalysis (15) UsingSonographicParametersofShoulderMajorTendonsinaShoulderPain
10
7
PopulationtoDiscriminateSupraspinatusFullThicknessTear (16) ApplicationofMultivariateAnalysisfortheIdentificationofHomogeneous
PopulationinSchizophrenia (17) (18) (19) (20) (i)
(ii) (21) (22) (23) (24) (25) (26) (27) (28) (29) Community dynamics of Scleractian corals Chard corals in northern
Taiwan (30) (31) N-3
11
103 4 9 102 2 2
103 6 6 102 2 2
103 11 26 103 1 3
Ph.D.
24 D 13 7 6
1. 103 12
B- 2. 104 6
B-
1. 1 2. 1 6
(1) (A) 3
12
user 3
user
(B) 3 (2)
(A) 3 (B) 3
3. 17 D 6
1
4 4 B-
104
13
24
1. 2.
3. 4.
5. 6.
B- 7. 8.
14
9.
1.
2.
3. 4.
1. 1 11 20 2 4 20
2. 1 1 2 6 3. 5-9 3 1
1 1
4. 5.
15
97 3 11
97 4 10
97 6 19
102 9 26
103 10 2
26 7 1
30 96
TOEFL 550 TOEFL CBT 213 TOEFL iBT 79 TOEIC 750 IELTS 6.0
4
103
16
user 4
00
0
0
0
0
0
0
0 000
0 0 0
0 0 0
*:
1
2
1 ()()
2 3
17
user 5
3
1
2 3
3 6 9 12
18
97.12.31 9705
98.9.1 9801
19
00
0
0
0
0
0
0
0
0 0 0
0 0 0
0 0 0
1. 7
(1)()
(2) 7 ( 1 31
7 31 ) 3 5
2.
3.
4. 5 1 5 31 5. 6.
1
1impact factor,I.F. 25 2impact factor,I.F. 50 3impact factor,I.F. 75 4 SCI 5 Biomedical EngineeringApplications, Basis, and Communications (
20
) 6
7
2
21
85 12 27 86 12 31 88 1 18
88 12 18 92 5 2 92 8 22
95 6 23 95 12 29 98 1 9
101 9 17 102 6 18
102 6 21 103 7 1
103 12 5
()
()
()
()
1.
2. () 1
3.
()
()
()
1.
A A+
1
22
user 6
user
2.
() ()
()
()
()
()
()
()
()
() ()
23
24
100 3 8
100 9 22
102.04.17
102.06.21
()
()
()
3 10
25
user 7
(102.06.21)
()
26
1 0 3 1 2 1 17
C C1(C1C ) C2(C2D ) C3(C3E )
102
CHIN4019/20 / 2/2 100
CHIN3003/4 / 3/3
CHIN3019/20 / 2/2
100 CHIN2007/8 / 2/2
CHIN2227/8 / 2/2 100
CHIN2005/6 / 2/2
Hist4046 - 3 103 2 A 103
Psy3014 1 103 2
27
user 8
1 0 3 1 2 2 17
3 Med 3066 2 104 1 102
3 Med 3067 2 104 1 102
3 Med 3061 2 104 1 102
3 Med 3062 2 104 1 102
Med 3061 2 97-101
Med 3066 2
Med 3062 2 97-101 Med 3067 2
1.
2. 5.
103
2 Forest3033 2 3 103
2 Forest4003 3 3 103
2 Forest3063 4 A 103
2 3 A 103
2 Forest2033 4 A 103
28
1 0 3 1 2 3 17
2 3 A 103
3 Forest3065 4 A 103
3 3 A 103
3 Forest3066 3 A
4 3 A 103
4 Forest4023 1 A 103
4 3 A 103
4 Forest4024 2 A 103
4 Forest4023 1 103 1
4 Forest4024 2 103 1
Chem1007 2
102
Chem1009 3
Chem1008 2
102
Chem1009 3
1. 1 2. 1 1
102
2 Forest3063 4 B 103
2 3 B 103
29
1 0 3 1 2 4 17
2 Forest2033 4 B 103
2 3 B 103
3 Forest3065 4 B 103
3 3 B 103
3 Forest3066 3 B
4 3 B 103
4 Forest4023 1 B 103
4 3 B 103
4 Forest4024 2 B 103
4 Forest4023 1 103 1
4 Forest4024 2 103 1
Chem1007 2
102
Chem1009 3
Chem1008 2
102
Chem1009 3
1. 1 2. 1 1
102
30
1 0 3 1 2 5 17
2 Forest3063 4 C 103
2 3 C 103
2 Forest2033 4 C 103
2 3 C 103
3 Forest3065 4 C 103
3 3 C 103
4 3 C 103
4 Forest4023 1 C 103
4 3 C 103
4 Forest4024 2 C 103
4 Forest4023 1 103 1
4 Forest4024 2 103 1
Chem1007 2
102
Chem1009 3
Chem1008 2
102
Chem1009 3
1. 1 2. 1 1
102
31
1 0 3 1 2 6 17
2 Forest3063 4 D 103
2 3 D 103
2 Forest2033 4 D 103
2 3 D 103
3 Forest3065 4 103
3 3 103
3 Forest3066 3 D
4 3 D 103
4 Forest4023 1 D 103
4 3 D 103
4 Forest4024 2 D 103
4 Forest4023 1 103 1
4 Forest4024 2 103 1
Chem1007 2
102
Chem1009 3
Chem1008 2
102
Chem1009 3
1. 1 2. 1 1
102
32
1 0 3 1 2 7 17
2 BICD1012 3 1 2 102
2 BICD2024 3 2 2 102
2 BICD3030 3 3 2 102
1 BICD1019 3 103 1 102
1 BICD1023 3 103 1 102
1 BICD1017 3 103 1 102
2 BICD2038 3 103 1 102
1 BICD1020 3 103 2 102
1 BICD1021 3 103 2 102
1 BICD1022 3 103 2 102
2 BICD2039 3 103 2 102
2 BICD2040 3 102 2 102
3 BICD3042 3 104 1 102
3 BICD3043 3 104 1 102
3 BICD3044 3 104 2 102
3 BICD3045 3 104 2 102
1 BICD1013 3 102
1 ECON1006 3 102 1 BICD2034 3 102 1 BICD1014 3 102 2 BICD2004 3 102 2 BICD2005 3 102
33
1 0 3 1 2 8 17
2 BICD5035 3 102 2 BICD2025 3 102 2 BICD2032 3 102 3 BICD5045 3 102 3 BICD5046 3 101 3 BICD3031 3 102 3 BICD4023 3 102
BICD4006 2 103 1
56 53 101
102
102
2 HORT3024 2 103 2 2 2 103
103
VM4016 2 103 2
VM4016 2
() 96-99 VM5070 2
34
1 0 3 1 2 9 17
VM5088 2
() 96-99 VM5089 2
103 2
2
96-99
2 BST2011 4 103 2 102
3 BST3022 4 104 1 102
2 BST2001 4 103 1 102
2 BST2002 4 103 2 102
BST2011 4
102 BChem3012 4
BST3022 4 102
BChem3013 4
BST2001 4 101
BST2011 4
BST2002 4
101 BST3022 4
BST2001 4 101
BChem3012 4
35
1 0 3 1 2 10 17
BST2002 4 101
BChem3013 4
100
100
Thea8002 3 103 1 A 2 1
103
Thea8004 3 104 1 A 2 1
Thea8003
3 103 2 B 2 1
Thea8005
3 104 2 B 2 1
Thea8001 1 103 2
Thea8999 0 103 1
24 1 6 17D 6 6 http://homepage.ntu.edu.tw/~theatre/rule-02.htm
103
4 8
24 103
24 7 17 98
36
1 0 3 1 2 11 17
12 6 104
99 99
TCSL7241 2 104 1 3 2 104
TCSL7242 2 104 2 3 2 104
TCSL7243 2 105 1 3 2 104
12 16 30 34 104
3 6 U http://gpti.ntu.edu.tw/main.php
103
1 GPTI7213 GPTI7214
33 103 2 103
1 GPTI7202 GPTI7203
33 103 2 103
3 U http://gpti.ntu.edu.tw/main.php
103
37
1 0 3 1 2 12 17
104
PSY 7242 1 103 2
ClinMD8054 1 103 1 103
ClinMD8055 1 103 1 103
ClinMD8056 1 103 1 103
ClinMD8332 1 103 1 103
ClinMD8333 1 103 1 103
ClinMD8334 1 103 1 103
ClinMD8335 1 103 1 103
ClinMD8336 1 103 1 103
ClinMD8337 1 103 1 103
ClinMD8201 1 103 1 103
ClinMD8202 1 103 1 103
ClinMD8203 1 103 1 103
ClinMD8338 1 103 1 103
ClinMD8339 1 103 1 103
38
1 0 3 1 2 13 17
ClinMD8340 1 103 1 103
ClinMD8041 1 103 1 103
ClinMD8042 1 103 1 103
ClinMD8043 1 103 1 103
ClinMD8341 1 103 1 103
ClinMD8342 1 103 1 103
ClinMD8343 1 103 1 103
ClinMD8344 1 103 1 103
ClinMD8345 1 103 1 103
ClinMD8346 1 103 1 103
ClinMD8347 1 103 1 103
ClinMD8348 1 103 1 103
ClinMD8349 1 103 1 103
103
()(C )(D )
ClinMD8054 1 103 1 103
ClinMD8055 1 103 1 103
ClinMD8056 1 103 1 103
39
1 0 3 1 2 14 17
ClinMD8332 1 103 1 103
ClinMD8333 1 103 1 103
ClinMD8334 1 103 1 103
ClinMD8003 1 103 1 103
ClinMD8004 1 103 1 103
ClinMD8005 1 103 1 103
ClinMD8335 1 103 1 103
ClinMD8336 1 103 1 103
ClinMD8337 1 103 1 103
ClinMD8201 1 103 1 103
ClinMD8202 1 103 1 103
ClinMD8203 1 103 1 103
ClinMD8338 1 103 1 103
ClinMD8339 1 103 1 103
ClinMD8340 1 103 1 103
ClinMD8041 1 103 1 103
ClinMD8042 1 103 1 103
ClinMD8043 1 103 1 103
ClinMD8341 1 103 1 103
ClinMD8342 1 103 1 103
ClinMD8343 1 103 1 103
40
1 0 3 1 2 15 17
ClinMD8344 1 103 1 103
ClinMD8345 1 103 1 103
ClinMD8346 1 103 1 103
ClinMD8347 1 103 1 103
ClinMD8348 1 103 1 103
ClinMD8349 1 103 1 103
103
()(C )(D ) 103
GIBMS7001 1 4 102 10 12 102
1.2 Enve 7090 3 D 104
1.2 Enve 7090 3 A 104 1 2 Enve7016 3 A 104 1 2 Enve7062 3 B 104
41
1 0 3 1 2 16 17
4 5 104
(
)
103
5 () D 6 104
(
)
103
4 () M 6 104
BICD7115 3 103 1 103
3 103 1 103
BICD7080 3 103 1 103
BICD7081 3 103 1 103
103
1 6
2 http://www.bicd.ntu.edu.tw/ 103
42
1 0 3 1 2 17 17
BICD7115 3 103 1 103
3 103 1 103
BICD8031 3 103 1 103
BICD8015 3 103
BICD8019 3 103 BICD8026 103
103
13 9
2http://www.bicd.ntu.edu.tw/ 103
Biot7016 1 103 1 103
Prog5074 4 103
Biot7013 2 102 2
103
Biot7015 2 103
Prog5074 4 U, M, D
103
U, M, D 4
( 4 ) 24 ()
103
43
()
103 1 2
()
()
()
()
44
user 9
user
45
1 2
103 12 8 1700 19:00
1
()
103 10 24 1
5
1/2+1/3
1/2+1/3
1/2+1/2
3
1/2+1/3( 2/3+1/2)
46
user 10
2 2
3
21/31
1001 60 21 27
1002 42 0 24
1011 43 14 20
1012 50 2 28
1021 52 9 37
1022 36 1 16
1031 35 8 16
101
16915 477 325
11688 344 264
9782 206 89
6325 184 122
5527 159 109
47
user
()
103 1 2
1.
2. 103
48
user 11
85 5 4 84 2 2
86 12 17 86 1 2
87 12 16 87 1 2
89 3 3189 89038089
90 4 290 90043845
93 6 11 93 1 2
94 3 18 93 2 1
94 5 20 93 2 2
95 3 17 94 2 1
98 1 9 97 1 2
99 6 11 98 2 2
99 10 15 99 1 1
101 10 12 101 1 1
49
50
() 103 1 2
()
()
()
1.
2.
3.
()()
() 1.
2.
3.
()
()
()
1.
2.
3.
()()
() 1.
2.
103 1 2
51
user 12
()
()
() ()
3.
()
()
() ()
52
1
100.6.10 99 2 2
100.6.21 101.1.6 100 1 2
101.1.18 121418 101.6.8 100 2 2 5681520
102.6.7 101 2 2 12 103.1.3 102 1 2 7
103.10.24 103 1 1 8
103.11.6
53
2
()
()()
() ()
()
()
54
3
()
55
4
()()
() 1.()
2. 3.
()()
()
1.
2.
3.
() () ()
56
5
()
X
(
)
()
57
6
()
()()
58
7
() ()
59
8
60
9
()
91-95 2 2
6 . 6 0
4
4
0
96-99 6 . 6 0
()1()3
0
100 6
. 6 0
1
3
0
2-6
4
CHIN 1000-1999 1 CHIN 2000-2999 2 CHIN 3000-3999 3
CHIN 4000-4996 4 4997-4999
CHIN 5000-5999
5 MED 6000-6999 6
CHIN 7000-7998 7
7999
CHIN 8000-8998
8999
61
()
1. 103-1(2)
2. 103-1(1)
103-1(2)
62
user
user
user
user
user
user
user
user
user 13
1
96.6.8 95 2 2
97.1.4 96 1 2
97.6.6 96 2 2
99.10.15 99 1 1
100.6.11 99 2 2
101.1.6 100 1 2
103.3.7 102 2 1
103.6.6 102 2 2
25
63
2
19 1
20 5%
64
B-
B-
65
user
user 14
B-
66
()()
()
()
()
()
67
A+All goals achieved beyond expectation
A All goals achieved
A-All goals achieved, but need some polish
B+Some goals well achieved
B Some goals adequately achieved
B-Some goals achieved with minor flaws
C+Minimum goals achieved
C Minimum goals achieved with minor flaws
C-Minimum goals achieved with major flaws
DUnsatisfactory,repeat recommended
EMinimum goals not achieved
FMinimum goals not achieved
X : Not graded due to unexcused absences or other reasons
A+ 4.3 90-100 95
A 4.0 85-89 87
A- 3.7 80-84 82
B+ 3.3 77-79 78
B 3.0 73-76 75
B- () 2.7 70-72 70
C+ 2.3 67-69 68
C 2.0 63-66 65
C- () 1.7 60-62 60
D 1.0 50-59 55
E 0 1-49 49
F 0 59() 50
X 0 0 0
68
user 15
user
user
1
100.6.10 99 2 2 102.6.7 101 2 2 6
()
()
(GPA) ()
(GPA)
(GPA)
()
102.6.14
69
2
A+(Allgoalsachievedbeyondexpectation) A(Allgoalsachieved) A-(Allgoalsachieved,butneedsomepolish) B+(Somegoalswellachieved) B(Somegoalsadequatelyachieved) B-(Somegoalsachievedwithminorflaws) C+(Minimumgoalsachieved) C(Minimumgoalsachievedwithminorflaws) C-(Minimumgoalsachievedwithmajorflaws) F(Minimumgoalsnotachieved) X:(Notgradedduetounexcusedabsencesorotherreasons)
()
A+ 4.3 90-100 95 A 4.0 85-89 87 A- 3.7 80-84 82 B+ 3.3 77-79 78 B 3.0 73-76 75
B-() 2.7 70-72 70
C+ 2.3 67-69 68 C 2.0 63-66 65
C-() 1.7 60-62 60
F 0 59() 50
X 0 0 0
70
3
(GPA)
GPA
GPA
GPA
GPA
GPA
GPA
4.30 100 3.80 85.67 3.30 79.00 2.80 73.33 2.30 69.00 1.80 62.004.29 99.63 3.79 85.50 3.29 78.90 2.79 73.20 2.29 68.90 1.79 61.804.28 99.27 3.78 85.33 3.28 78.80 2.78 73.07 2.28 68.80 1.78 61.604.27 98.90 3.77 85.17 3.27 78.70 2.77 72.93 2.27 68.70 1.77 61.404.26 98.53 3.76 85.00 3.26 78.60 2.76 72.80 2.26 68.60 1.76 61.204.25 98.17 3.75 84.83 3.25 78.50 2.75 72.67 2.25 68.50 1.75 61.004.24 97.80 3.74 84.67 3.24 78.40 2.74 72.53 2.24 68.40 1.74 60.804.23 97.43 3.73 84.50 3.23 78.30 2.73 72.40 2.23 68.30 1.73 60.604.22 97.07 3.72 84.33 3.22 78.20 2.72 72.27 2.22 68.20 1.72 60.404.21 96.70 3.71 84.17 3.21 78.10 2.71 72.13 2.21 68.10 1.71 60.204.20 96.33 3.70 84.00 3.20 78.00 2.70 72.00 2.20 68.00 1.70 60.004.19 95.97 3.69 83.88 3.19 77.90 2.69 71.93 2.19 67.90 4.18 95.60 3.68 83.75 3.18 77.80 2.68 71.85 2.18 67.80 4.17 95.23 3.67 83.63 3.17 77.70 2.67 71.78 2.17 67.70 4.16 94.87 3.66 83.50 3.16 77.60 2.66 71.70 2.16 67.60 4.15 94.50 3.65 83.38 3.15 77.50 2.65 71.63 2.15 67.50 4.14 94.13 3.64 83.25 3.14 77.40 2.64 71.55 2.14 67.40 4.13 93.77 3.63 83.13 3.13 77.30 2.63 71.48 2.13 67.30 4.12 93.40 3.62 83.00 3.12 77.20 2.62 71.40 2.12 67.20 4.11 93.03 3.61 82.88 3.11 77.10 2.61 71.33 2.11 67.10 4.10 92.67 3.60 82.75 3.10 77.00 2.60 71.25 2.10 67.00 4.09 92.30 3.59 82.63 3.09 76.90 2.59 71.18 2.09 66.90 4.08 91.93 3.58 82.50 3.08 76.80 2.58 71.10 2.08 66.80 4.07 91.57 3.57 82.38 3.07 76.70 2.57 71.03 2.07 66.70 4.06 91.20 3.56 82.25 3.06 76.60 2.56 70.95 2.06 66.60 4.05 90.83 3.55 82.13 3.05 76.50 2.55 70.88 2.05 66.50 4.04 90.47 3.54 82.00 3.04 76.40 2.54 70.80 2.04 66.40 4.03 90.10 3.53 81.88 3.03 76.30 2.53 70.73 2.03 66.30 4.02 89.73 3.52 81.75 3.02 76.20 2.52 70.65 2.02 66.20 4.01 89.37 3.51 81.63 3.01 76.10 2.51 70.58 2.01 66.10 4.00 89.00 3.50 81.50 3.00 76.00 2.50 70.50 2.00 66.00 3.99 88.83 3.49 81.38 2.99 75.87 2.49 70.43 1.99 65.80 3.98 88.67 3.48 81.25 2.98 75.73 2.48 70.35 1.98 65.60 3.97 88.50 3.47 81.13 2.97 75.60 2.47 70.28 1.97 65.40 3.96 88.33 3.46 81.00 2.96 75.47 2.46 70.20 1.96 65.20 3.95 88.17 3.45 80.88 2.95 75.33 2.45 70.13 1.95 65.00 3.94 88.00 3.44 80.75 2.94 75.20 2.44 70.05 1.94 64.80 3.93 87.83 3.43 80.63 2.93 75.07 2.43 69.98 1.93 64.60 3.92 87.67 3.42 80.50 2.92 74.93 2.42 69.90 1.92 64.40 3.91 87.50 3.41 80.38 2.91 74.80 2.41 69.83 1.91 64.20 3.90 87.33 3.40 80.25 2.90 74.67 2.40 69.75 1.90 64.00 3.89 87.17 3.39 80.13 2.89 74.53 2.39 69.68 1.89 63.80 3.88 87.00 3.38 80.00 2.88 74.40 2.38 69.60 1.88 63.60 3.87 86.83 3.37 79.88 2.87 74.27 2.37 69.53 1.87 63.40 3.86 86.67 3.36 79.75 2.86 74.13 2.36 69.45 1.86 63.20 3.85 86.50 3.35 79.63 2.85 74.00 2.35 69.38 1.85 63.00 3.84 86.33 3.34 79.50 2.84 73.87 2.34 69.30 1.84 62.80 3.83 86.17 3.33 79.38 2.83 73.73 2.33 69.23 1.83 62.60 3.82 86.00 3.32 79.25 2.82 73.60 2.32 69.15 1.82 62.40 3.81 85.83 3.31 79.13 2.81 73.47 2.31 69.08 1.81 62.20
71
4
()
()
()
(1)
(2)
(
)
()
()
()
()
()
72
89 1 3 89 1 3
89 1 6 89 1 1
89.12.20 89 1 2 98.06.15 97 2 2
()
()
()
()
1.
2.
73
user 16
1.
2.
1.
2.
1.
74
2.
1.
2.
3.
1.
2.
1.
2.
1.
2.
75
1.
2.
76
--
P260 941 4 0 0 3
P260 942 0 0 0 0
P260 951 0 1 0 0
P260 952 0 0 0 0
P260 961 3 0 0 2
P260 962 0 0 0 0
P260 971 2 1 0 2
P260 972 0 0 0 0
P260 981 0 0 0 0
P260 982 0 0 0 0
P260 991 0 0 0 0
P260 992 0 0 0 0
P260 1001 0 0 0 0
P260 1002 0 0 0 0
P260 1011 0 0 0 0
P260 1012 0 0 0 0
P260 1021 0 0 0 0
P260 1022 0 0 0 0
P260 1031 0 0 0 0
9 2 0 7
77
user 17
11
94
10 9 (94 496
3 97 2) 2
98 98
104
78
user 18
103 11 17 103
()(
)
()
()
()
20 ( C-)
79
user 19
80
8. 10312ALL1.() - 20152.Appled multivariate Quantitative methods final2.103.1.23.103.1.24.103.1.25.6.103-1-2--all
ALL8.10.-10.11.11.12.103111012.13.103 12 11-NEW14.15._15._16. 17.104103.09.1818._